APOGEE THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.96 USD | +3.31% |
|
+1.09% | +88.87% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.89B 241B |
|---|---|---|---|---|---|
| Net income 2024 * | -140M -11.68B | Net income 2025 * | -187M -15.6B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 288M 23.98B | Net cash position 2025 * | 462M 38.5B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-20.2
x | P/E ratio 2025 * |
-16.8
x | Employees | 91 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.21% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +3.33% | ||
| 1 week | +1.09% | ||
| Current month | +4.91% | ||
| 1 month | -6.39% | ||
| 3 months | +47.20% | ||
| 6 months | +231.26% | ||
| Current year | +88.87% |
1 week
49.57
55.31
1 month
43.6158.18
Current year
27.0572.29
1 year
14.1972.29
3 years
14.1972.29
5 years
14.1972.29
10 years
14.1972.29
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.43% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/24/10 | 52.88 | +3.16% | 94 112 |
| 08/24/08 | 51.26 | -1.84% | 181,945 |
| 07/24/07 | 52.22 | -3.85% | 188,503 |
| 06/24/06 | 54.31 | +0.22% | 227,298 |
| 03/24/03 | 54.19 | +3.81% | 346,103 |
Delayed Quote Nasdaq, May 10, 2024 at 01:11 am IST
More quotes
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Calendar
16/05/2024
- BofA Securities Health Care Conference
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
51.26
USD
Average target price
85.8
USD
Spread / Average Target
+67.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +88.87% | 2.89B | |
| +24.31% | 46.71B | |
| +48.83% | 41.8B | |
| -0.94% | 41.52B | |
| -5.86% | 29.55B | |
| +11.21% | 25.78B | |
| -20.90% | 19.26B | |
| +2.95% | 12.14B | |
| -2.20% | 12.08B | |
| +30.60% | 11.98B |
- Stock Market
- Equities
- APGE Stock